Roche Holding AG (SWX:ROP)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 276.52B +22.2% |
| Revenue (ttm) | 62.96B -0.8% |
| Net Income | 12.34B +30.9% |
| EPS | 15.33 +30.6% |
| Shares Out | 796.77M |
| PE Ratio | 22.54 |
| Forward PE | 16.36 |
| Dividend | 9.80 (2.84%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 660,829 |
| Open | 346.00 |
| Previous Close | 349.00 |
| Day's Range | 342.50 - 349.90 |
| 52-Week Range | 258.20 - 375.80 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 375.34 (+8.57%) |
| Earnings Date | Oct 22, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for ROP stock is "Buy." The 12-month stock price target is CHF 375.34, which is an increase of 8.57% from the latest price.
News
Roche Stocks Rises as Autonomous Labs Move AI Into Wet Research
Roche Stocks Rises as Autonomous Labs Move AI Into Wet Research
Roche’s Genentech reports new data from Voyager study of Vabysmo
Genentech, a member of the Roche (RHHBY) Group, announced new data from the Voyager study evaluating the effectiveness, durability and safety of Vabysmo in wet age-related macular degeneration, diabet...
Roche’s Genentech reports detailed results from evERA Breast Cancer study
Genentech, a member of the Roche (RHHBY) Group, announced that detailed results from the evERA Breast Cancer study, showing investigational giredestrant in combination with everolimus significantly im...
Genentech's Giredestrant Posts Positive Phase 3 Data Ahead Of November, December FDA Dates
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced that detailed Phase 3 evERA study results published in the New England Journal of Medicine showed that giredestrant combined with ...
Roche Highlights Real-World Vabysmo Performance Across Major Retinal Diseases At EURETINA
(RTTNews) - Roche (RHHBY) announced new data from the VOYAGER study showing that Vabysmo (faricimab) continued to demonstrate effectiveness, durability and safety in real-world clinical practice acros...
Roche Says Giredestrant- Everolimus Combo Significantly Improves PFS In ER+ Breast Cancer
(RTTNews) - Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW) announced Thursday that giredestrant combination significantly improved progression-free survival in ER-positive advanced breast ca...
Roche's Vabysmo Shows Real-World Effectiveness Across Retinal Diseases
(RTTNews) - Thursday, Roche (RHHBY) reported new data from the VOYAGER study showing that Vabysmo (faricimab) delivered durable effectiveness and a consistent safety profile in patients with wet age-r...
Genentech Presents New Data at EURETINA, Highlighting Vabysmo's Real-World Effectiveness and Safety Across Major Retinal Conditions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the VOYAGER study evaluating the effectivene...
Genentech's Giredestrant Combination Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer in Phase III evERA Data Published in The New England Journal of Medicine
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--evERA results published in The New England Journal of Medicine underscore the potential of investigational giredestrant in ER+ advanced breast ...
FDA Grants Priority Review for Roche's Fenebrutinib MS Treatment (RHHBY)
FDA Grants Priority Review for Roche's Fenebrutinib MS Treatment (RHHBY)
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche is increasingly looking like a notable contender in this fast-growing area.
Roche unit launches LightMix Newborn TREC/SMN1/HBB kit
Roche (RHHBY) announced that TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix Newborn TREC/SMN1/HBB kit, an in vitro diagnostic test for newborn screening in countries accepti...
Roche’s Genentech announces FDA approves NDA for fenebrutinib
Genentech, a member of the Roche (RHHBY) Group, announced that the U.S. FDA has accepted the company’s NDA under priority review for fenebrutinib, an investigational non-covalent Bruton’s tyrosine kin...
Roche (RHHBY) Launches Newborn Screening Kit, Reinforcing Dividend Appeal Amid Modest Overvaluation
Roche (RHHBY) Launches Newborn Screening Kit, Reinforcing Dividend Appeal Amid Modest Overvaluation
Roche Gets FDA Filing Acceptance For Fenebrutinib In MS; Launches Newborn Screening Test
(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, announced two regulatory developments, with the U.S. FDA accepting its New Drug Application (NDA) for Fenebrutinib in relapsing multiple scl...
Genentech: FDA Grants Priority Review To Fenebrutinib NDA For Relapsing And Primary Progressive MS
(RTTNews) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW) announced Wednesday that the U.S. Food and Drug Administration has accepted its New Drug Application or ND...
Roche's fenebrutinib is the first BTK inhibitor to receive U.S. FDA filing acceptance in both relapsing and primary progressive multiple sclerosis
Basel, 30 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under prio...
Roche launches newborn screening test for three severe genetic conditions
This test expands Roche's early diagnostics portfolio by screening for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) simultaneously . Ca...
Genentech Breaks Ground On $750 Mln Manufacturing Expansion In Oregon For Drug Delivery Devices
(RTTNews) - Genentech, a member of the Roche Group (RHHBY), has launched a $750 million expansion of its manufacturing facility in Hillsboro, Oregon, aimed at increasing U.S. manufacturing capacity fo...
Roche Bets On Data Generation And AI Independence To Strengthen Drug Development
(RTTNews) - Roche Holding AG (RHHBY) outlined plans to expand the use of artificial intelligence across its research operations, highlighting data generation and AI independence as key drivers of futu...
Genentech Breaks Ground on $750 Million Manufacturing Expansion in Hillsboro, Oregon
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today broke ground on a $750 million expansion of its manufacturing facility in Hills...
Chugai Regains Rights To Emugrobart, Shifts Focus Back To SMA Development
(RTTNews) - Chugai Pharmaceutical Co., Ltd. (4519) announced that development of Emugrobart (GYM329) for obesity has been discontinued, with all rights to the drug being returned by Roche (RHHBY).
Roche Plans Autonomous AI Labs To Accelerate Drug Discovery
(RTTNews) - Swiss pharmaceutical Roche Holding AG (RHHBY) outlined plans on Monday to develop autonomous AI-driven laboratories as part of its efforts to accelerate research and development and improv...
Roche outlines plans to move towards autonomous AI labs
Swiss pharmaceutical giant Roche outlined plans to move towards autonomous AI labs to speed up research and development discovery at its pharma investor day on Monday.
Roche Holding AG Transcript: Pharma Day 2026
Revised summary: Significant progress was made in pipeline quality, financial performance, and modernization, with 20 NMEs targeted for launch by 2030. Strong AI-driven R&D and manufacturing support key launches in oncology, neurology, immunology, ophthalmology, and CVRM, with multiple milestones expected in 2027.